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Background-—Hypertension is an important risk factor for cardiovascular events in patients with peripheral artery disease;
however, optimal blood pressure targets for these patients are poorly defined. This study investigated the association between
systolic blood pressure (SBP) and cardiovascular events in a prospectively recruited patient cohort with peripheral artery disease.
Methods and Results-—A total of 2773 patients were included and were grouped according to SBP at recruitment (≤120 mm Hg,
n=604; 121–140 mm Hg, n=1065; and >140 mm Hg, n=1104). Adjusted Cox proportional hazards analyses suggested that
patients with SBP ≤120 mm Hg were at greater risk of having a major cardiovascular event (myocardial infarction, stroke, or
cardiovascular death) than patients with SBP of 121–140 mm Hg (adjusted hazard ratio, 1.36; 95% CI, 1.08–1.72; P=0.009).
Patients with SBP >140 mm Hg had an adjusted hazard ratio of 1.23 (95% CI, 1.00–1.51; P=0.051) of major cardiovascular events
compared with patients with SBP of 121–140 mm Hg. These findings were similar in sensitivity analyses only including patients
receiving antihypertensive medications or focused on patients with a minimum of 3 months of follow-up.
Conclusions-—This cohort study suggests that patients with peripheral artery disease and SBP ≤120 mm Hg are at increased risk
of major cardiovascular events. The findings suggest caution in intensive SBP lowering in this patient group. ( J Am Heart Assoc.
2019;8:e010748. DOI: 10.1161/JAHA.118.010748.)
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P eripheral artery disease (PAD) comprises a group ofocclusive and aneurysmal diseases resulting from nar-
rowing and occlusion of the peripheral arteries, which are
estimated to affect 10% of adults worldwide.1–4 Approximately
20% of patients with PAD die from a cardiovascular event within
5 years of diagnosis; therefore, medical management of
cardiovascular risk factors is the primary focus of treatment.5,6
Hypertension is an important risk factor for complications in
patients with PAD. Prior studies suggest the prevalence of
hypertension in patients with PAD to be between 35% and 55%.7
There is evidence from randomized clinical trials suggesting
that administering antihypertensive medications in patients
with PAD and hypertension reduces the incidence of cardio-
vascular events by 20% to 30%.8,9 Therefore, current clinical
guidelines recommend that patients with PAD should receive
antihypertensive medications if their blood pressure (BP) is
>140/90 mm Hg.10 The current definition of what constitutes
clinically important hypertension warranting medical treatment
is controversial.11,12 Recent American College of Cardiology/
American Heart Association guidelines recommend commenc-
ing antihypertensive treatment when systolic BP (SBP) is
≥130 mm Hg, whereas other guidelines recommend antihy-
pertensive treatment if BP is >140/90 mm Hg.11–13
A recent study in patients with PAD has suggested poor
control of BP in this population.14 One possible reason for this
could be the limited data on the value of BP control
specifically in discrete populations of patients with PAD. A
recent Cochrane review concluded that there was no
overwhelming evidence available on the benefit of treating
hypertension in patients with PAD.15 The level to which the BP
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should be lowered in these patients is also controversial.
Recently, 2 large trials that included patients with PAD,
performed by the ACCORD (Action to Control Cardiovascular
Risk in Diabetes) trial and SPRINT (SBP Intervention Trial)
research groups, assessed the efficacy of intensive SBP
lowering to <120 mm Hg, as opposed to more conventional
SBP targets (<140 mm Hg), to reduce major cardiovascular
events.16,17 The trials had contradictory results. Findings from
SPRINT suggested that intensive SBP lowering reduced the
incidence of cardiovascular events substantially, whereas the
ACCORD trial results indicated that intense SBP lowering did
not reduce cardiovascular events.16,17 Another trial that also
included patients with PAD reported that the incidence of
cardiovascular events was lowest among patients with an
average SBP between 135 and 145 mm Hg.18 The relationship
between SBP and cardiovascular events was best represented
by a J-shaped curve. Several studies have demonstrated this
relationship in a variety of different populations.19–22
These data emphasize that the optimal SBP target for
patients with PAD remains controversial. Randomized trials
frequently include only selected patients with PAD and,
therefore, data for heterogeneous cohorts of real-world
patients are important to qualify findings from such trials. In
this current study, the relationship between SBP and cardio-
vascular events was examined in a large heterogeneous group
of patients with PAD. The aims of this study were to examine
the following:
1. The prevalence of hypertension using different definitions
based on SBP targets in previous trials, including >120 and
>140 mm Hg.12,13,16
2. The association of SBP categories (≤120, 121–140, and
>140 mm Hg) with cardiovascular events.
Methods
Requests for access to data, analytic methods, and study
materials should be made to the corresponding author.
Study Design and Participants
This investigation was designed as part of an ongoing
prospective cohort study that aims to identify risk factors
associated with PAD diagnosis and outcome. The study
commenced in 2002 and remains ongoing. Patients were
recruited from inpatient and outpatient vascular services in
Australia, including The Townsville Hospital, the Mater Hospi-
tal Townsville, Gosford Vascular Services, and The Royal
Brisbane and Women’s Hospital.
For inclusion in the current study, patients had to have
PAD, including lower/upper limb atherothrombosis; carotid
stenosis or aneurysm of the aorta or peripheral arteries,
diagnosed by a vascular specialist; and the assessment of BP
at recruitment. BP, risk factors, and medications of the
patients were only recorded at study entry. The study was
performed in accordance with the Declaration of Helsinki, and
ethical approval was granted from the respective institutional
ethics committees. Written informed consent was also
obtained from all participants.
Definition and Measurements of Risk Factors
Smoking status was classified as ever (including current and
former smoker) or never smoker.23–25 Hypertension and
diabetes mellitus were defined by a history of diagnosis or
treatment for these conditions.23–25 Coronary heart disease
(CHD) was defined by a history of myocardial infarction (MI),
angina, or treatment for CHD.23–25 Body mass index was
measured as previously described.26 Estimated glomerular
filtration rate was calculated, as previously described, using
the Chronic Kidney Disease Epidemiology collaboration
group formula because we have previously reported this to
most accurately predict complications in patients with
PAD.27
Definition of Presenting Problem
Patients presenting with one of the following PAD problems
were included in this study: (1) Asymptomatic carotid artery
stenosis: Diagnosed when at least one carotid artery has
≥50% stenosis or occlusion, identified by carotid duplex, but
the absence of physician-confirmed symptoms of focal
transient ischemic attack, amaurosis fugax, or stroke, as
previously described.28 (2) Nonthreatening limb ischemia:
This included patients with symptoms related to obstruction
of limb arteries, as confirmed by a vascular specialist by
identification of absence of limb pulses, ankle-brachial
Clinical Perspective
What Is New?
• The optimal blood pressure (BP) targets in patients with
peripheral artery disease are controversial.
• This large observational study found that patients with
peripheral artery disease who had systolic BP ≤120 mm Hg
at recruitment were at increased risk of subsequent major
cardiovascular events than those with systolic BP of 121 to
140 mm Hg at recruitment.
What Are the Clinical Implications?
• This study identifies patients with peripheral artery disease
and systolic BP ≤120 mm Hg as at high risk of major
cardiovascular events.
• The findings also raise some concern over aggressive BP
lowering in patients with peripheral artery disease.
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pressure index <0.9, and/or significant stenosis (>50%) or
occlusion of limb arteries on computed tomographic
angiography or duplex imaging that did not meet criteria for
critical limb ischemia.24,26 (3) Aneurysm of the aorta or
peripheral arteries: Aortic aneurysm was defined as maximum
aortic diameter ≥30 mm.24–26 Iliac artery aneurysm was
defined by common or internal iliac artery diameters ≥15 and
≥8 mm, respectively. Femoral artery aneurysm was defined by
common femoral or superficial femoral artery diameter of
≥15 mm. Popliteal artery aneurysm was defined as popliteal
artery diameter ≥9 mm, as previously described.29 (4) Symp-
tomatic carotid artery stenosis: Defined as the presence of
≥50% stenosis or occlusion of at least one carotid artery
identified with carotid duplex with the presence of physician-
confirmed symptoms of focal transient ischemic attack,
amaurosis fugax, or stroke, as previously described.28 (5)
Critical limb ischemia: Rest pain, arterial ulcer, or gangrene of
the limb attributable to atherothrombosis of the limb arteries.
Peripheral atherothrombosis was confirmed, as detailed
above.24,26
Blood Pressure
This was measured at recruitment using a digital BP monitor,
Omron Intellisense (HEM–907), according to current clinical
guidelines.13 Resting BP was measured at the patient’s first
visit.
Medications
The patient’s medications were recorded at recruitment,
including antiplatelets, diuretics (frusemide, thiazides, potas-
sium sparing, and indapamide), a blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
b blockers, calcium channel blockers, statins, fibrates,
metformin, and insulin.
Outcomes
Participants were followed up as outpatient or inpatient as
part of their normal care. Outcome data were recorded during
clinical reviews on prospectively defined case report forms. A
vascular specialist also reviewed charts and hospital elec-
tronic records of patients. Data were linked with hospital
admission records, as previously described.30,31 Linked data
were obtained from the Queensland Hospital Admitted
Data Collection, which is regularly audited to minimize data
inaccuracies.32 The primary outcome was the first occurrence
of a major cardiovascular event, including MI, stroke, or
cardiovascular death. The secondary outcomes included the
components of the primary outcome considered individually
and all-cause mortality. Patients were censored at the
outcome event date or at the date of the last follow-up for
those who had not experienced the outcome.
Statistical Analysis
Patients were categorized into 3 groups, according to their SBP:
(1) SBP ≤120 mm Hg (representing patients who had SBP
controlled according to SPRINT),16 (2) SBP 121 to 140 mm Hg
(represents those who had BP controlled as recommended
within some PAD treatment guidelines [European Society of
Cardiology/Gabb et al]10,13 [reference group]), and (3) SBP
>140 mm Hg (patients who did not meet European Society of
Cardiology/Gabb et al guideline-defined control of SBP).10,13
Data were analyzed using the SPSS v 23 and R statistical
software packages. The quantitative data were not normally
distributed, which was confirmed using the Shapiro-Wilk test.
Hence, continuous data are presented as median and
interquartile range and were compared between groups using
Kruskal-Wallis tests. Nominal data are reported as count and
percentages and were compared using v2 tests. Monte-Carlo
simulations suggest that a multivariate regression model is
powered sufficiently when 10 outcome events per df of the
predictor variable were observed.33–35 A recent study con-
ducted by our vascular research group recorded 505 outcome
events, including MI, stroke, and death, in 2137 patients during
a median follow-up of 1.3 years. The event rate during this
follow-up was 23.6%.27 Hence, the incidence of primary
outcome for this study was estimated to be20%. We planned
to adjust our analysis for a maximum of 9 independent
traditional cardiovascular risk factors and potential con-
founders, of which 2 had multiple categories. On the basis of
these estimates, a sample size of >2000 patients was planned
because this would be well powered to determine the
association of different SBP categories with cardiovascular
outcomes. Cox proportional hazard analyses were used to
assess the association between SBP and the primary and
secondary outcomes using multivariable models adjusted for
age (categorized into 3 groups based on tertiles), sex, PAD
presenting problem (categorized into 5 groups, as discussed
above), smoking, diabetes mellitus, CHD, body mass index, and
statin and frusemide prescription. These covariates were
chosen for inclusion in the Cox models because they are
established predictors of cardiovascular events or because
they were significantly unequally distributed among the SBP
groups. These analyses were conducted in 2574 patients with
complete data for all of these covariates. Additional analyses
were performed to analyze the association between diastolic
BP (DBP; n=2496) or pulse pressure (PP; n=2496), with the
outcomes of interest including the covariates listed above,
except SBP, in the models. For these analyses, patients were
categorized into 3 groups according to their DBP ([1]
<80 mm Hg, [2] 80 to 89 mm Hg, and [3] ≥90 mm Hg) or
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PP tertiles ([1] ≤53 mm Hg, [2] 54–68 mm Hg, and [3]
>68 mm Hg). Sensitivity analyses were performed, including
estimated glomerular filtration rate, SBP, and DBP (not PP) as
well as all the other risk factors and medications listed above
into the models in 2358 patients. Further sensitivity analyses
were also performed by excluding patients with follow-up
<3 months (1835 patients included) and excluding patients
who were not taking any antihypertensive medications (2030
patients included). None of the adjusted models presented
violated the assumptions for Cox proportional hazards analy-
ses. P<0.05 was considered significant for all the analyses.
Results
Study Population
A total of 2773 patients diagnosed with PAD were included in
the first aim of this study. The main presenting problems of the
patients were asymptomatic carotid disease (236 [8.5%]),
nonthreatening limb ischemia (614 [22.1%]), aortic or periph-
eral aneurysm (1288 [46.5%]), symptomatic carotid disease
(358 [12.9%]), and critical limb ischemia (277 [10.0%]).
At recruitment, 604 patients (21.8%) had an SBP
≤120 mm Hg, 1065 (38.4%) had an SBP between 121 and
140 mm Hg, and the remaining 1104 (39.8%) had an SBP
>140 mm Hg. Hence, according to different definitions, the
prevalence of hypertension in this cohort was 78.2% (SBP
>120 mm Hg) or 39.8% (SBP >140 mm Hg).
The patients from the 3 different SBP groups significantly
differed in the prevalence of the following risk factors and
medications: age, sex, history of an aneurysm, CHD, and
prescription of diuretics (frusemide and potassium-sparing
diuretics) and antihypertensive medications, such as angio-
tensin receptor blockers and calcium channel blockers
(Table 1). All other risk factors and medications were
distributed similarly between the 3 SBP groups.
Primary Outcome
The association of BP with the primary composite outcome of
MI, stroke, or cardiovascular death was assessed in a
subpopulation of 2574 patients with complete clinical data.
During a median follow-up of 1.7 years (interquartile range,
0.1–4.9 years), 563 patients (21.9%) had an MI, stroke, or
cardiovascular death. Adjusted Cox proportional hazards
analyses suggested that patients with SBP ≤120 mm Hg
(hazard ratio, 1.36; 95% CI, 1.08–1.72; P=0.009) were at
greater risk of having a major cardiovascular event compared
with patients with SBP between 121 and 140 mm Hg
(Table 2, Figure 1). Patients with SBP >140 mm Hg had an
adjusted hazard ratio of 1.23 (95% CI, 1.00–1.51; P=0.051;
Table 2) of major cardiovascular events.
Secondary Outcomes
MI, stroke, cardiovascular death, and all-cause mortality
occurred in 279 (10.8%), 183 (7.1%), 283 (11.0%), and 534
(20.7%) of patients, respectively. As for the primary outcome,
the adjusted Cox proportional hazards analyses suggested an
increased risk of MI alone in patients with SBP >140 or ≤120
mm Hg compared with patients in the reference SBP group
(Table 2, Figure 2). No increased risk of stroke alone was
observed in patients with SBP ≤120 or >140 mm Hg by
comparison to those with SBP 121 to 140 mm Hg (Table 2,
Figure S1). An increased risk of cardiovascular and all-cause
mortality was also detected in patients with SBP ≤120, but
not >140, mm Hg in comparison to those with SBP 121 to
140 mm Hg (Table 2, Figures S2 and S3).
Sensitivity Analyses
Sensitivity analysis, including the additional covariates of DBP
and estimated glomerular filtration rate, showed similar
findings (n=2358) (Table S1). A sensitivity analysis including
only patients who were taking ≥1 antihypertensive medication
(n=2030) demonstrated similar findings to the main analysis
(Table 2). Patients with SBP ≤120 or >140 mm Hg were at
increased risk of major cardiovascular events and MI alone
(Table 2). An increased risk of stroke alone, cardiovascular
death, and all-cause mortality was also observed in patients
with SBP ≤120 mm Hg compared with those with SBP 121 to
140 mm Hg in this sensitivity analysis (Table 2). A second
sensitivity analysis was performed, only including patients
who had at least 3 months of follow-up (n=1835). After
adjusting for other risk factors, patients with SBP ≤120 and
>140 mm Hg had an increased risk of major cardiovascular
events (Table 2). In this sensitivity analysis, only patients with
SBP >140 mm Hg had an increased risk of MI alone. Patients
with SBP ≤120 mm Hg had an increased risk of all-cause
mortality (Table 2).
Association of DBP and PP With Events
There was no association observed between DBP, PP, and
outcomes of interest (Tables S2 and S3).
Discussion
The current study suggests that poorly controlled SBP
remains prevalent in patients with PAD. Depending on the
definition, the prevalence of poorly controlled SBP in this
study was 40% (SBP >140 mm Hg) or 80% (SBP
>120 mm Hg) at recruitment. Patients with PAD and SBP
>140 mm Hg were at increased risk of MI, emphasising the
importance of SBP control. In contrast, patients with PAD and
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Table 1. Demographic and Baseline Characteristics of the Patients According to SBP
Demographic and Clinical Characteristics
SBP, mm Hg (n=2773)
P Value≤120 121–140 >140
1 N 604 1065 1104
2 Age, y 69.2 (62.5 – 75.7) 70.8 (64.1 – 76.2) 71.7 (65.7 – 77.8) <0.001
3 Sex 0.016
Male 445 (73.7) 848 (79.6) 842 (76.3)
Female 159 (26.3) 217 (20.4) 262 (23.7)
4 BMI, kg/m2 27.4 (23.7 – 30.8) 27.8 (24.9 – 31.0) 27.6 (24.5 – 31.0) 0.085
5 PAD problem 0.079
Asymptomatic carotid stenosis 43 (7.1) 84 (7.9) 109 (9.9) 0.097
Nonthreatening limb ischemia 129 (21.4) 220 (20.6) 265 (24.0) 0.150
All aneurysms 281 (46.5) 530 (49.8) 477 (43.2) 0.009
Symptomatic carotid stenosis 85 (14.1) 131 (12.3) 142 (12.9) 0.583
Critical limb ischemia 66 (10.9) 100 (9.4) 111 (10.0) 0.600
6 Smoking
Never 95 (15.8) 150 (14.1) 178 (16.1) 0.401
Ever 508 (84.2) 912 (85.9) 925 (83.9)
7 DM 167 (27.6) 296 (27.9) 306 (27.7) 0.992
8 Hypertension 457 (75.7) 818 (76.8) 896 (81.2) <0.001
9 CHD 309 (51.2) 520 (49.0) 499 (45.2) 0.042
10 Stroke 71 (11.8) 141 (13.4) 142 (12.9) 0.656
11 eGFR (ml/min/1.73 m(2)) 77 (60 – 90) 76 (59 – 89) 74 (57 – 88) 0.073
12 No. of antihypertensive agents
0 146 (24.2) 244 (22.9) 214 (19.4) 0.038
1 158 (26.2) 258 (24.2) 330 (29.9) 0.011
2 164 (27.2) 308 (28.9) 348 (31.5) 0.140
3 102 (16.9) 197 (18.5) 152 (13.8) 0.010
4 26 (4.3) 45 (4.2) 47 (4.3) 0.997
5 7 (1.2) 10 (0.9) 13 (1.2) 0.847
13 Medications
Aspirin 389 (64.5) 718 (67.6) 740 (67.0) 0.417
Other antiplatelets 133 (22.1) 220 (20.7) 235 (21.3) 0.812
CCB 154 (25.5) 323 (30.4) 355 (32.2) 0.016
Frusemide 78 (12.9) 120 (11.3) 79 (7.2) <0.001
Thiazides 48 (7.9) 96 (9.0) 107 (9.7) 0.485
Potassium-sparing diuretic 19 (3.1) 16 (1.5) 8 (0.7) 0.001
Indapamide 14 (2.3) 50 (4.7) 47 (4.3) 0.050
a Blocker 13 (2.2) 22 (2.1) 30 (2.7) 0.568
b Blocker 232 (38.5) 372 (35.0) 360 (32.6) 0.051
ACEI 251 (41.6) 427 (40.2) 426 (38.6) 0.453
ARB 122 (20.2) 268 (25.2) 326 (29.5) <0.001
Statins 415 (68.8) 768 (72.3) 779 (70.6) 0.309
Continued
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SBP ≤120 mm Hg had an increased incidence of major
cardiovascular events, MI alone, cardiovascular death alone,
and all-cause mortality. These findings were similar in
sensitivity analyses.
There are several possible explanations for the excess of
events in patients with low SBP. First, it could be attributable
to an excess of cardiovascular morbidity, such as heart failure,
in patients with SBP ≤120 mm Hg. The prescription of
frusemide (a medication commonly used to treat heart failure)
was more common in patients with SBP ≤120 mm Hg than in
patients in the other SBP groups. However, SBP ≤120 mm Hg
was still associated with a higher incidence of cardiovascular
events in analyses adjusted for other cardiovascular risk
factors (including frusemide), suggesting the high incidence of
cardiovascular events in patients with SBP ≤120 mm Hg was
not explained by an excess of cardiovascular risk factors.
Another possible explanation could be that some patients
had an adverse response to SBP lowering. In a sensitivity
Table 1. Continued
Demographic and Clinical Characteristics
SBP, mm Hg (n=2773)
P Value≤120 121–140 >140
Fibrates 15 (2.5) 47 (4.4) 43 (3.9) 0.134
Metformin 89 (14.8) 172 (16.2) 186 (16.8) 0.533
Insulin 26 (4.3) 63 (5.9) 64 (5.8) 0.331
14 Follow-up, y 2.0 (0.1 – 5.3) 2.0 (0.2 – 5.1) 1.5 (0.1 – 4.4) 0.085
The data are expressed as median (interquartile range) for continuous data and number (percentage) for categorical data. Some of the data were missing, as follows: BMI, n=192; smoking,
n=5; DM, n=6; hypertension, n=5; ischemic heart disease, n=6; stroke, n=16; eGFR, n=151; and medications, n=9. ACEI indicates angiotensin-converting enzyme inhibitor; ARB,
angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; CHD, coronary heart disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; PAD,
peripheral artery disease; SBP, systolic blood pressure.
Table 2. Association of Different SBP Categories With Outcome Events in the Whole Cohort, Only Patients Taking
Antihypertensive Medications, and Patients With >3 Months of Follow-Up
Outcome SBP, mm Hg
Whole Cohort (n=2574)
Patients Treated With
Antihypertensive Medications
(n=2030)
Excluding Patients With <3 mo of Follow-Up
(n=1835)
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Major CVE* 121–140 1.00 (Reference) N/A 1.00 (Reference) N/A 1.00 (Reference) N/A
≤120 1.36 (1.08–1.72)† 0.009 1.55 (1.21–1.99)† <0.001 1.34 (1.05–1.70)† 0.017
>140 1.23 (1.00–1.51)†‡ 0.051 1.25 (1.00–1.57)† 0.049 1.27 (1.03–1.56)† 0.027
MI 121–140 1.00 (Reference) N/A 1.00 (Reference) N/A 1.00 (Reference) N/A
≤120 1.38 (1.00–1.91)§ 0.053 1.51 (1.06–2.13)§ 0.021 1.32 (0.95–1.84)§ 0.103
>140 1.44 (1.08–1.91)§ 0.013 1.44 (1.06–1.96)§ 0.019 1.44 (1.08–1.92)§ 0.012
Stroke 121–140 1.00 (Reference) N/A 1.00 (Reference) N/A 1.00 (Reference) N/A
≤120 1.24 (0.83–1.84)k 0.290 1.59 (1.05–2.41)k 0.029 1.23 (0.82–1.83) 0.312
>140 1.09 (0.77–1.54)k 0.637 1.05 (0.71–1.55)k 0.812 1.08 (0.76–1.54) 0.653
Cardiovascular death 121–140 1.00 (Reference) N/A 1.00 (Reference) N/A 1.00 (Reference) N/A
≤120 1.39 (1.01–1.91) 0.044 1.47 (1.04–2.07) 0.029 1.33 (0.95–1.86) 0.097
>140 1.13 (0.84–1.53) 0.404 1.23 (0.89–1.68) 0.210 1.19 (0.88–1.61) 0.263
All-cause mortality 121–140 1.00 (Reference) N/A 1.00 (Reference) N/A 1.00 (Reference) N/A
≤120 1.34 (1.07–1.69) 0.013 1.34 (1.04–1.73) 0.024 1.31 (1.03–1.66) 0.025
>140 1.03 (0.83–1.28) 0.779 1.04 (0.83–1.32) 0.717 1.03 (0.82–1.28) 0.810
Regression models were adjusted for age categories, sex, peripheral artery disease presenting problem, smoking, diabetes mellitus, coronary heart disease, body mass index, and statin
and frusemide prescription. CVE indicates cardiovascular event; HR, hazard ratio; MI, myocardial infarction; N/A, not applicable; SBP, systolic blood pressure.
*Defined as MI, stroke, or cardiovascular death.
†Patient presenting problem and age at recruitment were stratified in this model to conform to the proportional hazards assumption.
‡The lower limit of the CI was 0.993, which was rounded off to the second decimal place.
§Coronary heart disease was stratified in this model to conform to the proportional hazards assumption.
kDiabetes mellitus was stratified in this model to conform to the proportional hazards assumption.
DOI: 10.1161/JAHA.118.010748 Journal of the American Heart Association 6
BP and Cardiovascular Risk in Patients With PAD Thomas Manapurathe et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 11, 2019
analysis, the association between SBP ≤120 mm Hg and
events remained in patients receiving antihypertension med-
ications, supporting the possibility that intense lowering of
SBP could have harmful effects in some patients with PAD. It
is possible, although unproven, that not all patients with
cardiovascular diseases should be treated so aggressively for
hypertension, which may, in part, explain the disparate
findings of the SPRINT and ACCORD trials.
Most current guidelines suggest that the SBP level of
patients should be maintained at ≤140 mm Hg.8,11–13 SPRINT
demonstrated a 43% decrease in the relative risk of death
from cardiovascular causes in patients randomized to inten-
sive SBP lowering targeted at <120 mm Hg compared with
patients allocated to less intensive SBP lowering targeted at
<140 mm Hg.16 On the contrary, the ACCORD trial did not
establish any significant reduction in cardiovascular events,
with intensive antihypertensive treatment aimed at lowering
SBP to <120 mm Hg.17 The prevalence of cardiovascular risk
factors among patients in SPRINT was less when compared
with the cohort of patients in this study. The proportion of
patients who had ever smoked in the current cohort was
significantly higher than in SPRINT (84.6% versus 55.5%).
SPRINT also excluded patients with a history of stroke and
diabetes mellitus, whereas these patients were included in
both the ACCORD trial and the current study. The higher
cardiovascular risk of the patients in this current study was
apparent by higher event rates in the current study compared
with SPRINT.
The optimal target BP in patients with PAD has not been
specifically investigated. Although SPRINT included a subset
of patients with PAD, the researchers recommendations
cannot be generalized in a clinical setting because SPRINT
excluded patients with diabetes mellitus and previous studies
have suggested a strong association between diabetes
mellitus and PAD.36–39 Patients with PAD often present with
concomitant diseases, and more than a quarter of the
patients in this cohort had diabetes mellitus at recruitment.
The INVEST (INternational VErapamil SR-Trandolapril) trial,
which included patients with concomitant CHD and PAD,
demonstrated a J-shaped relationship between SBP and the
Figure 1. Kaplan-Meier survival curves illustrating freedom from major cardiovascular events
(composite of myocardial infarction, stroke, or cardiovascular death), according to systolic blood
pressure (SBP) in patients with peripheral artery disease. The red line represents patients with SBP
between 121 and 140 mm Hg. The blue line represents patients with SBP >140 mm Hg, and the green
line represents patients with SBP ≤120 mm Hg. Numbers below the table indicate the number of patients
at risk at each time point. Differences were compared using the log-rank test (P=0.029).
DOI: 10.1161/JAHA.118.010748 Journal of the American Heart Association 7
BP and Cardiovascular Risk in Patients With PAD Thomas Manapurathe et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on April 11, 2019
composite of all-cause mortality, nonfatal MI, or stroke.18
Patients without PAD did not demonstrate this relationship,
suggesting that patients with PAD may require a different BP
target. The lowest rate of cardiovascular events in the INVEST
trial was observed in patients with SBP 135 to 145 mm Hg.
The results of this study are consistent with the prospective
observational study by the CLARIFY (ProspeCtive observa-
tional LongitudinAl RegIstry oF patients with stable coronary
arterY disease) group, which included patients with stable
CHD, and also with previous post hoc analyses from trials in
patients with CHD and hypertension.19,21,40 Previous studies
have also demonstrated the J-shaped relationship between
SBP and cardiovascular events in high-risk patients with
cardiovascular diseases, diabetes mellitus, or target organ
damage.41,42
This study has several strengths and limitations. The
strength of the study included the recruitment of a large
cohort of patients presenting to vascular clinics on a routine
basis and treated in real-life practice. There was a difference
in sample sizes of the 3 SBP groups, which may have
influenced the findings. Overall, the study was well powered,
however, because the smallest SBP group (≤120 mm Hg) still
included >600 patients. The study was part of a prospective
cohort study and not a randomized trial. Thus, the associa-
tions demonstrated are subject to the possibility of residual
confounding, which we attempted to minimize by adjusting for
recognised cardiovascular risk factors. It remains possible
that factors we did not measure and, therefore, could not
adjust for led to residual confounding. Also, SBP was routinely
recorded only at recruitment and, thus, we could not assess
the association of SBP recorded over time with cardiovascular
events. Furthermore, because this is an observational study,
not an interventional trial targeting a specific SBP, there is
potential for reverse causality. Because data on heart failure
were not collected during recruitment, frusemide prescription
was selected to reflect this. This may have caused additional
confounding.
Additional analyses were performed to analyze the asso-
ciation between DBP or PP and cardiovascular events. The
findings support past research, suggesting that SBP has a
stronger association with clinical events than other markers
of high BP.43,44
In conclusion, the findings of the current observational
study identify patients with PAD and SBP ≤120 and
>140 mm Hg as at high risk of cardiovascular events and
death. The findings of this study do not contradict those of
Figure 2. Kaplan-Meier survival curves illustrating freedom from myocardial infarction (MI)
according to systolic blood pressure (SBP) in patients with peripheral artery disease. The red
line represents patients with SBP between 121 and 140 mm Hg. The blue line represents
patients with SBP >140 mm Hg, and the green line represents patients with SBP
≤120 mm Hg. Numbers below the table indicate the number of patients at risk at each
time point. Differences were compared using the log-rank test (P=0.073).
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well-designed clinical trials targeting BP reduction given the
different design of those studies, which address different
questions.
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Table S1. Association of different systolic blood pressure categories with outcome events 
in the subgroup including additional covariates DBP and eGFR.  
Outcome SBP 
(mmHg) 
Subgroup (n = 2358) 
 
HR (95%CI) P value 
Major 
CVE* 
121 - 140 1.00 (ref) N/A 
≤ 120 1.30 (1.02 – 1.65)† 0.036 
>140 1.24 (1.00 – 1.54)† 0.049 
MI 121 - 140 1.00 (ref) N/A 
≤ 120 1.30 (0.93 – 1.82)ǂ 0.131 
>140 1.44 (1.07 – 1.94)ǂ 0.016 
Stroke 121 - 140 1.00 (ref) N/A 
≤ 120 1.07 (0.70 – 1.62)§ 0.767 
>140 1.20 (0.83 – 1.72)§ 0.334 
Cardio-vascular death 121 - 140 1.00 (ref) N/A 
≤ 120 1.32 (0.95 – 1.85) 0.102 
>140 1.12 (0.82 – 1.52) 0.483 
All- cause mortality 121 - 140 1.00 (ref) N/A 
≤ 120 1.31 (1.03 – 1.67) 0.029 
>140 1.01 (0.81 – 1.26) 0.933 
 
The results are expressed in Hazards ratio (HR) and 95% confidence interval (CI). Regression 
models were adjusted for age categories, sex, PAD presenting problem, smoking, diabetes, 
CHD, DBP, BMI, eGFR, prescriptions for statin and frusemide.  
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*Defined as MI, stroke or cardiovascular death. 
† Patient presenting problem and age at recruitment were stratified in this model to conform 
to the proportional hazards assumption. 
ǂ CHD was stratified in this model in order to conform to the proportional hazards 
assumption. 
§ Diabetes was stratified in this model in order to conform to the proportional hazards 
assumption.  
BMI – Body mass index, CHD – coronary heart disease, CVE – cardiovascular event, DBP – 
Diastolic blood pressure, eGFR – estimated glomerular filtration rate, MI – myocardial 
infarction, SBP – systolic blood pressure. 
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Table S2. Association of different diastolic blood pressure categories with outcome 
events in the whole cohort. 
Outcome DBP 
(mmHg) 
Whole cohort (n = 2496) 
 
HR (95%CI) P value 
Major 
CVE* 
80 - 89 1.00 (ref) N/A 
< 80 1.00 
(0.81 – 1.23)† 
0.991 
≥ 90 0.91 
(0.65 – 1.27)† 
0.567 
MI 80 - 89 1.00 (ref) N/A 
< 80 1.13 
(0.83–1.53)ǂ 
0.431 
≥ 90 1.08 
(0.68–1.73)ǂ 
0.743 
Stroke 80 - 89 1.00 (ref) N/A 
< 80 1.06 
(0.75–1.51)§ 
0.742 
≥ 90 0.58 
(0.30–1.13)§ 
0.109 
Cardio- vascular  
death 
80 - 89 1.00 (ref) N/A 
< 80 0.82 
(0.61–1.10) 
0.193 
≥ 90 0.77 0.299 
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(0.47–1.26) 
All-cause  
mortality 
80 - 89 
1.00 (ref) N/A 
< 80 0.92 
(0.74–1.14) 
0.444 
≥ 90 0.86 
(0.61–1.23) 
0.413 
 
The results are expressed in Hazards ratio (HR) and 95% confidence interval (CI). Regression 
models were adjusted for age categories, sex, PAD presenting problem, smoking, diabetes, 
CHD, BMI, statin and frusemide prescription. 
*Defined as MI, stroke or cardiovascular death. 
† Patient presenting problem and age category were stratified in this model to conform to the 
proportional hazards assumption. 
ǂ CHD was stratified in this model in order to conform to the proportional hazards 
assumption. 
§ Diabetes was stratified in this model in order to conform to the proportional hazards 
assumption.  
BMI – Body mass index, CHD – coronary heart disease, CVE – cardiovascular event, DBP – 
diastolic blood pressure, MI – myocardial infarction. 
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Table S3. Association of different pulse pressure categories with outcome events in the 
whole cohort. 
Outcome PP 
(mmHg) 
Whole cohort (n = 2496) 
 
HR (95%CI) P value 
Major 
CVE* 
54 - 68 1.00 (ref) N/A 
≤ 53 0.97 
(0.78 – 1.21)† 
0.784 
> 68 1.07 
(0.86 – 1.33)† 
0.548 
MI 54 - 68 1.00 (ref) N/A 
≤ 53 0.90 
(0.65–1.24)ǂ 
0.517 
> 68 1.13 
(0.84 –1.52)ǂ 
0.406 
Stroke 54 - 68 1.00 (ref) N/A 
≤ 53 0.93 
(0.63–1.37)§ 
0.705 
> 68 1.14 
(0.79–1.65)§ 
0.470 
Cardio-vascular 
 death 
54 - 68 1.00 (ref) N/A 
≤ 53 1.06 
(0.77–1.46) 
0.734 
> 68 1.05 0.778 
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(0.77–1.42) 
All-cause  
mortality 
54 - 68 
1.00 (ref) N/A 
≤ 53 1.05 
(0.84–1.32) 
0.662 
> 68 0.97 
(0.78–1.22) 
0.823 
 
The results are expressed in Hazards ratio (HR) and 95% confidence interval (CI). Regression 
models were adjusted for age categories, sex, PAD presenting problem, smoking, diabetes, 
CHD, BMI, statin and frusemide prescription. 
*Defined as MI, stroke or cardiovascular death. 
† Patient presenting problem and age category were stratified in this model to conform to the 
proportional hazards assumption. 
ǂ CHD and statin were stratified in this model in order to conform to the proportional hazards 
assumption. 
§ Diabetes was stratified in this model in order to conform to the proportional hazards 
assumption.  
BMI – Body mass index, CHD – coronary heart disease, CVE – cardiovascular event, MI – 
myocardial infarction, PP - pulse pressure. 
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Figure S1. Kaplan- Meier survival curves illustrating freedom from stroke according to 
SBP in patients with PAD. 
 
 
The red line represents patients with SBP between 121 to 140 mmHg. The blue line 
represents patients with SBP >140 mmHg and green line represents patients with SBP ≤ 120 
mmHg. Numbers below the table indicate the number of patients at risk at each time point. 
Differences were compared using log-rank test (p=0.52). Abbreviations:   PAD – peripheral 
artery disease and SBP – systolic blood pressure. 
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Figure S2. Kaplan- Meier survival curves illustrating freedom from cardiovascular 
death according to SBP in patients with PAD. 
 
The red line represents patients with SBP between 121 to 140 mmHg. The blue line 
represents patients with SBP >140 mmHg and green line represents patients with SBP ≤ 120 
mmHg. Numbers below the table indicate the number of patients at risk at each time point. 
Differences were compared using log-rank test (p=0.15). Abbreviations:   PAD – peripheral 
artery disease and SBP – systolic blood pressure.  
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Figure S3. Kaplan- Meier survival curves illustrating freedom from all-cause mortality 
according to SBP in patients with PAD.  
 
The red line represents patients with SBP between 121 to 140 mmHg. The blue line 
represents patients with SBP >140 mmHg and green line represents patients with SBP ≤ 120 
mmHg. Numbers below the table indicate the number of patients at risk at each time point. 
Differences were compared using log-rank test (p=0.082). Abbreviations:  PAD – peripheral 
artery disease and SBP – systolic blood pressure.  
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